NASDAQ · GYRE
Gyre Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GYRE: Nov 6, 2026
Gyre Therapeutics, Inc. Common Stock is estimated to report earnings on 11/06/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $0.05.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $-0.10 | $-0.19 | 2 |
| Dec 2026 | $-0.16 | $-0.11 | $-0.20 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · RTTNews- Zacks · Oct 29, 7:35 AM EDTIncyte (INCY) Reports Q3 Loss, Beats Revenue EstimatesIncyte (INCY) delivered earnings and revenue surprises of +9.77% and +5.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Oct 22, 4:33 PM EDTGyre Therapeutics, Inc. Enters Into New Employment Agreements on October 16, 2026On October 16, 2026, Gyre Therapeutics, Inc. entered into an employment agreement with Ying Luo, Ph.D., to continue as Chief Executive Officer. The agreement provides for Dr. Luo’s at-will employment, an annual base salary of $500,000, and a 2026 target annual bonus of $150
- RTTNews · Aug 10, 3:37 AM EDTGyre Q2 Loss Widens As Revenue Edges Lower; Reaffirms Revenue Guidance(RTTNews) – Gyre Therapeutics, Inc. (GYRE), a commercial-stage biopharmaceutical company, announced financial results for the second quarter of 2026, reflecting a wider net loss and a slip in revenue.
- Zacks · Aug 7, 8:20 AM EDTGyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue EstimatesGyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 5:40 PM EDTCytokinetics (CYTK) Reports Q2 Loss, Beats Revenue EstimatesCytokinetics (CYTK) delivered earnings and revenue surprises of +7.98% and +40.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 27, 8:18 AM EDTNew Strong Sell Stocks for May 27thGYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.
- Zacks · May 7, 7:45 AM EDTGyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue EstimatesGyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of +16.67% and -33.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 12, 7:10 AM EDTGyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss EstimatesGyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +2.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 10, 8:35 AM EDTADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue EstimatesADC Therapeutics (ADCT) delivered earnings and revenue surprises of +87.50% and +20.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 9, 5:15 PM EDTVoyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue EstimatesVoyager Therapeutics (VYGR) delivered earnings and revenue surprises of +15.08% and +57.97%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Feb 24, 7:30 PM ESTDay One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue EstimatesDay One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of -19.98% and +11.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Nov 7, 8:54 AM ESTGYRE THERAPEUTICS, INC. Announces Advance In Q3 Income(RTTNews) – GYRE THERAPEUTICS, INC. (GYRE) reported a profit for its third quarter that Increased, from the same period last year
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Gyre Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.